Greenland Mines Ltd (NASDAQ: GRML) has announced a series of corporate milestones as it transitions into a focused rare earths and critical minerals company, including plans to spin off its biotechnology division in the fourth quarter of 2026. The company also revealed that Nasdaq has formally approved its application relating to a March 2026 transaction, resolving prior deficiencies and bringing the company into full compliance with listing requirements.
The announcement comes alongside the completion of the acquisition of the Sarfartoq project on Sept. 1, following approval by the Government of Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. According to the company, planned annual neodymium-praseodymium oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels, during each of the project's nine scheduled operating years.
This strategic shift underscores the growing importance of rare earth elements, particularly neodymium and praseodymium, which are critical for permanent magnets used in electric vehicles, wind turbines, and other clean energy technologies. As global demand for these materials surges, reducing reliance on Chinese refining is a key geopolitical and economic priority. By advancing the Sarfartoq project, Greenland Mines aims to contribute to a more diversified supply chain.
In conjunction with the operational updates, Greenland Mines is reshaping its board. Riad El-Dada and Dr. Shalom Hirschman are stepping down, with capital markets veteran Jason Hawkins joining as the company advances Sarfartoq and its Skaergaard palladium-gold-platinum project. This leadership change is expected to bring additional expertise in capital markets and project development, which could be pivotal as the company seeks to fund and develop these large-scale assets.
The decision to spin off the biotech division, which includes Klotho's KLTO-202 for ALS, reflects a sharper focus on mining. This move allows the company to dedicate resources and management attention to its core mining projects, potentially enhancing shareholder value by unlocking separate valuations for the distinct businesses.
The implications of this announcement are significant for the industry and investors. For the rare earth market, the Sarfartoq project could become a substantial non-Chinese source of NdPr oxide, helping to meet rising demand. For Greenland Mines, the compliance with Nasdaq listing requirements and the completion of the acquisition remove overhangs and position the company for potential growth. Investors will be watching closely as the company progresses towards the biotech spin-off and continues to develop its critical minerals portfolio.
For more details, visit the full press release at https://ibn.fm/QN1U9.
